US 11,806,372 B2
Methods of treating and diagnosing IBD associated with r. gnavus and/or r. gnavus group IBD colonization
Andrew Brantley Hall, Cambridge, MA (US); Ramnik Xavier, Brookline, MA (US); Curtis Huttenhower, Boston, MA (US); Moran Yassour, Cambridge, MA (US); and Hera Vlamakis, Arlington, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 16/604,866
Filed by The Broad Institute, Inc., Cambridge, MA (US); The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
PCT Filed Apr. 20, 2018, PCT No. PCT/US2018/028604
§ 371(c)(1), (2) Date Oct. 11, 2019,
PCT Pub. No. WO2018/195448, PCT Pub. Date Oct. 25, 2018.
Claims priority of provisional application 62/488,554, filed on Apr. 21, 2017.
Prior Publication US 2020/0155617 A1, May 21, 2020
Int. Cl. A61K 35/741 (2015.01); A61P 29/00 (2006.01)
CPC A61K 35/741 (2013.01) [A61P 29/00 (2018.01)] 21 Claims
 
1. A method of treating IBD in a human subject comprising
a. determining from a gut microbiome sample whether the gut microbiome comprises Ruminococcus gnavus,
b. determining relative abundance of R. gnavus, and if the relative abundance of R. gnavus is at least 5%,
c. diagnosing the subject as having IBD, and
d. administering to the subject an effective amount of at least one antimicrobial agent effective for eliminating or suppressing R. gnavus.